di Giuliana Rapaciolo – HIMed 27, maggio 2023

Per leggere l’articolo in pdf
cliccare a questo link.

Bibliografia

• 1. SEYLE H, Einfuhrung in die lehre von adaptionsyndrom Thieme publ, Stuttgart, 1953
• 2. TANAKA TH, LEISMAN G, NISHJJO K Dynamic electromyographic response following acupuncture: possible influence of synergistic cohordination lnt J Neurosci, 1998; 95:51-61
• 3. TIPLER PA Invito alla fisica Zanichelli publ, Bologna, 2001
• 4. TREDSTAD RL Matrix glycoproteins and proteoglycans in Textbook of Rheumatology section I; Structure and function of joints, connective tissue, and muscle Kelley WN ed, 5th edition, Saunders co publ, Philadelphia, 1997, pp 37-54
• 5. TUCKERMAN ME, MARA D et al. On the quantum nature of the shared proton in Hydrogen bonds Science, 1997; 275:817-20
• 6. VIRCHOW R Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre Hirschwald publ, Berlin, 1858
• 7. VOLL R La posizione topografica dei punti di elettroagopuntura Piccin publ, Padova, 1982 154. WASER A The logarithmic distribution in nature Raum & Zeit, 2003; 123:35-40
• 8. WEI S, SHI Z, CASTLEMAN AW Mixed cluster ions as a structure probe: experimental evidence for clathrate structure 1 Che m Phys, 1991; 94:3268-73
• 9. WEIHE E Neuropeptides in primary afferent neurons in The primary afferent neuron Zenker W, Neuhuber WL eds, PLenum co publ, New York, 1990, pp 127-59
• 10. WHEELER JA, ZUREK WH eds Quantum theory and measurement Princeton Univ press publ, Princeton, 1983
• 11. WIDAKOWICH J Microdose therapy: dilution versus potentiation? Med Hypot, 1997; 49:437-41
• 12. WIGHT ThN et al. Proteoglycans. Structure and function in Cell Biology of Extracellular Matrix Hay ED ed, 2nd edition, Plenum press publ, New York-London, 1991, pp 45-78
• 13. WOLKOWSKI ZW Hierarchical aspects of sinergy and coherence in biological systems in Photon emission from biologica! Systems 1EZOWSKA B ed, World Scientific publ, 1987, pp 22-50
• 14. WOLKOWSKI ZW Sur l’evolution de certains concepts physiques das le sciences de la vie revue Internationale de Sistemique, 1988; 2:459
• 15. WUCKERPFENNING KW, STROMINGER JL Molecular mimicry in T-cell-mediated autoimmunity: viral peptides activate human T-cell clones specific for myelin basic protein Cell, 1995; 80:695-705
• 16. WUCHERPFENNING KW Structural basis of molecular mimicry J Autoimmun, 2001; 16:201-9
• 17. YAMADA KM, Fibronectin and other structural proteins in, Cell biology of extracellular Matrix Hey ED ed, 2nd edition, Plenum press publ, New York-London, 1983, pp 95-114
• 18. YORK JA, ROCK KL Antigen processing and presentation by the class I major histocompatibility complex Annu Rev Immunol, I996; 14:369-96
• 19. ZAK M, WILLIAMS CP Quantum neural nets Internat J Theoretical Physics, 1998; 37:651-84
• 20. ZERLAUTH B et al. Histologie der akupunkte Deutsches Zschr Akup, 1992; 35:34-8
• 21. ZHANG BZ Studies on the morphology and function of meridian lines with reference to neurogenic inflammation by ICR tissue Deutsches Zschr Akup, 1996; 39:29-38
• 22. ZHAO P Rheumatic arthritis treated with acupuncture. Clinical observation of 368 cases lnt J Clin Acupunct, 1993; 4:419-21
• 23. ZHENG Y, BROWN FLH Photon emission from driven single molecules J Chem Phys, 2003; 11814-28
• 24. Boyd LJ. A Study of the Simile in Medicine, Philadelphia: Boericke and Tafel, 1936Schulz H. Über die Theorie der Arzneimittelwirkun Virchows Archiv 1877; 108: 423-434
• 25. Schulz H. Über Hefegifte Arch fuer Physiol 1888; 42: 517-541
• 26. Martius F. Das Arndt-Schulz Grundgesetz. Muench Med Wschr 1923; 70: 1005-1006
• 27. Oberbaum M, Cambar J. Hormesis: dose-dependent reverse effects of low and very low doses. In Ultra High Dilutions, edited by PC Endler and J Schulte. Dordrecht: Kluwer Acad Publ, pp. 5-18, 1994
• 28. Townsend JF, Luckey TD. Hormoligosis in pharmacology. J Am Med Ass 1960; 173: 44-48
• 29. Stebbing ARD. Hormesis: the stimulation of growth by low levels of inhibitors. Sci Tot Environ 1982; 22: 213-234 7 Furst A. Hormetic effects in pharmacology: pharmacological inversions as prototypes for hormesis. Health Phys 1987; 52: 527-530
• 30. Calabrese EJ, McCarthy ME, Kenyon E. The occurrence of chemically induced hormesis. Health Phys 1987; 52: 531-541
• 31. Linde K, Jonas WB, Melchart D, et al. Critical review and meta-analysis of serial agitated dilutions in experimental toxicology. Hum Exp Toxicol 1994; 13: 481-492
• 32. Bastide M. Immunological examples on ultra high dilution research. In Ultra High Dilutions, edited by PC Endler and J Schulte. Dordrecht: Kluwer Acad Publ, pp. 27-33, 1994
• 33. Bellavite P, Signorini A. Homeopathy, a Frontier in Medical Science. Controlled Studies and Theoretical Foundations. Berkeley: North Atlantic Books, 1995
• 34. Poitevin B, Davenas E, Benveniste J. In vitro immunological degranulation of human basophils is modulated by Lung histamine and Apis mellifica. Brit J Clin Pharmacol 1988; 25: 439-444
• 35. Sainte Laudy J, Belon P. Inhibition of human basophil activation by high dilutions of histamine. Agent Actions 1993; 38: C245-247
• 36. Sainte-Laudy J, Belon P. Analysis of immunosuppressive activity of serial dilutions of histamine on human basophil activation by flow cytometry. Inflamm Res 1996; 45 (S1): 33-34
• 37. Bellavite P, Chirumbolo S, Lippi G, et al. Homologous priming in chemotactic peptide stimulated neutrophils. Cell Biochem Funct 1993; 11: 93-100
• 38. Bellavite P, Chirumbolo S, Lippi G, et al. Dual effects of formylpeptides on the adhesion of endotoxin-primed human neutrophils. Cell Biochem Funct 1993; 11: 231-239
• 39. Bellavite P, Carletto A, Biasi D, et al. Studies of skin-window exudate human neutrophils. Complex patterns of adherence to serum-coated surfaces in dependence on FMLP doses. Inflammation 1994; 18: 575-587
• 40. Iyengard R. Gating by cyclic AMP: expanded role for an old signaling pathway. Science 1996; 271: 461-463
• 41. Wiegant FAC, van Wijk R. Self-recovery and the similia principle: an experimental model. Complem Ther Med 1996; 4: 90-97
• 42. Wolff S. Are radiation-induced effects hormetic? Science 1989; 245: 57
• 43. Luckey TD. Low-dose irradiation. Advantage east! Radiat Protect Management 1993; 10: 59-63
• 44. Goldman M. Cancer risk of low-level exposure. Science 1996; 271: 1921-1822
• 45. Lapp C, Wurmser L, Ney J. Mobilization de l’arsenic fixé chez le cobaye sous l’influence des doses infinitesimales d’arseniate. Therapie 1955; 10: 625-638
• 46. Cambar J, Desmouliere A, Cal JC, et al. Mise en évidence de l’effet protecteur de dilutions homéopathiques de Mercurius corrosivus vis-à-vis de la mortalité au chlorure mercurique chez la souris. Ann Homéopathiques Fr 1983; 5: 160-167
• 47. Cazin JC, Cazin M, Gaborit JL, et al. A study of the effect of decimal and centesimal dilutions of Arsenic on the retention and mobilisation of Arsenic in the rat. Human Toxicol 1987; 6: 315-320
• 48. Palmerini CA, Codini M, Floridi A, et al. The use of Phosphorus 30 CH in the experimental treatment of hepatic fibrosis in rats. In: Omeomed92, edited by C Bornoroni. Bologna: Editrice Compositori, pp. 219-226, 1993
• 49. Ashby B. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets. Molec Pharmacol 1990; 38: 46-5
• 50. Sergeeva MG, Gonchar MV, Grishina ZV, Mevkh AT, Varfolomeyev SD. Low concentrations of nonsteroidal anti-inflammatory drugs affect cell functions. Life Sci 1995; 56: 313-31
• 51. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid? protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279-282
• 52. Smith JA. Neutrophils, host defense, inflammation: a double-edged sword. J Leukocyte Biol 1994; 56: 672-677
• 53. Änggàrd E. Nitric oxide: mediator, murderer, medicine. Lancet 1994; 343: 1199-1206 32 Skerret PJ. Substance P causes pain, but also heals. Science 1990; 249: 625
• 54. Adams DO, Hamilton TA. Macrophages as destructive cells in host defense. In Inflammation, 2d edition, edited by J I Gallin, I M Goldstein and R Snyderman. New York: Raven Press, pp. 637-662, 1992
• 55. Metz SA, Halter JB, Robertson RP. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus. J Clin Endocrin Metab 1979; 48: 827-835
• 56. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051
• 57. Griffin JH. The thrombin paradox. Nature 1995; 378: 337-338
• 58. Brain P, Cousens R. An equation to describe dose-responses where there is stimulation of growth at low doses. Weed Res 1989; 29: 93-96 38 Van Ewijk PH, Hoekstra JA. Calculation of the EC50 and its confidence interval when subtoxic stimulus is present. Ecotoxicol Environ Safety 1993; 25: 25-32
• 59. Pal et al. 2002.
• 60. Bianchi I, Pommier L. Grande dizionario enciclopedico di Omeopatia e Bioterapia, 2007 Nuova ipsa Editore s.r.l.
• 61. Escalante T, Shannon J, Moura-da-Silva AM, Gutiérrez JM, Fox JW. Arch Biochem Biophys. 2006 Nov 15; 455(2): 144-53. Epub 2006 Oct 6. Novel insights into capillary vessel basement membrane damage by snake venomhemorrhagic metalloproteinases: a biochemical and immunohistochemical study.
• 62. Teixeira Cde F, Fernandes CM, Zuliani JP, Zamuner SF. Mem Inst Oswaldo Cruz. 2005 Mar; 100 Suppl 1:181-4. Epub 2005 Jun 14. Inflammatory effects of snake venom metalloproteinases.
• 63. Marsh N, Williams V. Toxicon. 2005 Jun 15; 45(8): 1171-81. Epub 2005 Apr 7. Practical applications of snake venom toxins in haemostasis.
• 64. Jia LG, Shimokawa K, Bjarnason JB, Fox JW. Toxicon. 1996 Nov-Dec; 34(11-12): 1269-76. Snake venom metalloproteinases: structure, function and relationship to the ADAMs family of proteins.
• 65. Pinto AF, Terra RM, Guimaraes JA, Fox JW. Arch Biochem Biophys. 2007 Jan 1; 457(1): 41-6. Epub 2006 Nov 10. Mapping von Willebrand factor A domain binding sites on a snake venommetalloproteinase cysteine-rich domain.
• 66. Matsui T, Hamako J. Toxicon. 2005 Jun 15; 45(8): 1075-87. Epub 2005 Apr 22. Structure and function of snake venom toxins interacting with human von Willebrand factor.
• 67. Matsui T, Hamako J, Matsushita T, Nakayama T, Fujimura Y, Titani K. Biochemistry. 2002 Jun 25; 41(25): 7939-46. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
• 68. Ito M, Hamako J, Sakurai Y, Matsumoto M, Fujimura Y, Suzuki M, Hashimoto K, Titani K, Matsui T. Biochemistry. 2001 Apr 10; 40(14): 4503-11. Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinasewith two disintegrin-like sequences.
• 69. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Curr Med Chem Cardiovasc Hematol Agents. 2003 Jun; 1(2): 143-9. Structure-activity relationships of snake toxins targeting platelet receptors, glycoprotein Ib-IX-V and glycoprotein VI.
• 70. Andrews RK, Berndt MC. Toxicon. 2000 Jun; 38(6): 775-91. Snake venom modulators of platelet adhesion receptors and their ligands.
• 71. Wijeyewickrema LC, Berndt MC, Andrews RK. Toxicon. 2005 Jun 15; 45(8): 1051-61. Epub 2005 Apr 19. Snake venom probes of platelet adhesion receptors and their ligands.
• 72. Perutelli P. Recenti Prog Med. 1995 Apr; 86(4): 168-74. Disintegrins: potent inhibitors of platelet aggregation.
• 73. Williams JA. Pathol Biol (Paris). 1992 Oct; 40(8): 813-21. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors.
• 74. Lu X, Lu D, Scully MF, Kakkar VV. Curr Med Chem Cardiovasc Hematol Agents. 2003 Jun; 1(2): 189-96. Modulation of integrin-binding selectivity by mutation within the RGD-loop of snakevenom proteins: a novel drug development approach.
• 75. Gutiérrez JM, Rucavado A. Biochimie. 2000 Sep-Oct; 82(9-10): 841-50. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage.
• 76. Moura-da-Silva AM, Laing GD, Paine MJ, Dennison JM, Politi V, Crampton JM, Theakston RD. Eur J Immunol. 1996 Sep; 26(9): 2000-5. Processing of pro-tumor necrosis factor-alpha by venom metalloproteinases: a hypothesis explaining local tissue damage following snake bite.
• 77. Laing GD, Clissa PB, Theakston RD, Moura-da-Silva AM, Taylor MJ. Eur J Immunol. 2003 Dec; 33(12): 3458-63. Inflammatory pathogenesis of snake venom metalloproteinase-induced skin necrosis.
• 78. Escalante T, Rucavado A, Fox JW, Gutiérrez JM. J Proteomics. 2011 Aug 24; 74(9): 1781-94. doi: 10.1016/j.jprot.2011.03.026. Epub 2011 Apr 6. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases.
• 79. Ferreira RN, Machado de Avila RA, Sanchez EF, Maria WS, Molina F, Granier C, Chávez-Olórtegui C. Toxicon. 2006 Dec 15; 48(8): 1098-103. Epub 2006 Aug
• 80. Antibodies against synthetic epitopes inhibit the enzymatic activity of mutalysin II, ametalloproteinase from bushmaster snake venom.
• 81. Souza CT, Moura MB, Magalhaes A, Heneine LG, Olortegui CC, Diniz CR, Sanchez EF. Comp Biochem Physiol B Biochem Mol Biol. 2001 Sep; 130(2): 155-68. Inhibition of mutalysin II, metalloproteinase from bushmaster snake venom by human alpha2-macroglobulin and rabbit immunoglobulin.
• 82. Sanchez EF, Souza CT, Bello CA, Richardson M, Oliveira EB, Magalhaes A. Toxicon. 2003 Jun; 41(8): 1021-31. Resolution of isoforms of mutalysin II, the metalloproteinase from bushmaster snakevenom.
• 83. Andrews RK, Kroll MH, Ward CM, Rose JW, Scarborough RM, Smith AI, López JA, Berndt MC. Biochemistry. 1996 Sep 24; 35(38): 12629-39. Binding of a novel 50-kilodalton alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and glycoprotein Ib-mediated platelet activation.
• 84. Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Biochemistry. 1989 Oct 17; 28(21): 8317-26. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.
• 85. Ward CM, Andrews RK, Smith AI, Berndt MC. Biochemistry. 1996 Apr 16; 35(15): 4929-38. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin